Loading stock data…
KYMR
$84.10-1.98 (-2.30%)
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kymera Therapeutics, Inc. in the Healthcare sector is trading at $84.10. The stock is currently 18% below its 52-week high of $103.00, remaining 23.0% above its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why KYMR maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$84.10
Potential Upside
5%
Whystock Fair Value$88.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus22 analysts
Mean target$118.27+40.6%
Range$91.00 – $140.00
Fundamentals
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.44%
Volume
Today's trading volume
455,678
Recent News
How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential
Kymera Therapeutics is seeing only a slight adjustment in its modeled fair value, with the estimate moving from US$119.14 to US$118.86 per share. That kind of fine tuning lines up with recent Street commentary, where bullish and bearish analysts are largely debating how much weight to give KT-621 and the broader degrader pipeline rather than making wholesale changes to their long term views. As you read on, you will see what is driving these shifts and how to track the evolving Kymera...
AMD upgraded, Reddit downgraded: Wall Street's top analyst calls
AMD upgraded, Reddit downgraded: Wall Street's top analyst calls
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, American Eagle Outfitters, GlobalFoundries, IAC, Merck, Palantir Technologies, Reddit, and More
Pre-Market Stock Futures: Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower. This news comes after a bounce-back Tuesday that benefited from lower oil prices, some strong earnings, and solid buying from retail investors. At the same time, hedge funds continue to ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, American Eagle Outfitters, GlobalFoundries, IAC, Merck, Palantir Technolo
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
As you might know, Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) just kicked off its latest first-quarter results with some...
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.